Enzalutamide, a potent inhibitor of the androgen receptor (AR) [83], may have antiviral activity in the prostate glands of male COVID-19 patients but has no therapeutic effect in patients with a COVID-19 lung infection. This evidence concerns the gene AR and COVID-19.